The effects of ICS 205-930, a 5-HT antagonist, on arrhythmias and catecholamine release during canine myocardial ischaemia and reperfusion

European Journal of Pharmacology
S J CokerJ R Parratt

Abstract

The effects of ICS 205-930 [3 alpha-tropanyl)-1H-indole-3-carboxylic acid ester), an antagonist of 5-HT at neuronal M receptors, were examined in anaesthetised greyhounds subject to acute coronary artery occlusion and reperfusion. Intravenous administration of 0.3 or 2.0 mg kg-1 of ICS 205-930 did not significantly alter haemodynamics or blood gases. The higher dose had marked antiarrhythmic activity. The total number of ischaemia-induced extrasystoles was reduced to 167 +/- 64 compared with 467 +/- 99 in controls. Ventricular fibrillation induced by reperfusion after 40 min of ischaemia was also significantly reduced from 80 to 33%. Immediately following release of the coronary artery occlusion significant increases in plasma noradrenaline and dopamine concentrations were detected in local coronary venous blood draining from the ischaemic area in control dogs. This catecholamine release was also evident in the dogs which received 2 mg kg-1 ICS 205-930 but was less marked. Thus the antiarrhythmic activity of ICS 205-930 may be related to antagonism of detrimental effects of 5-HT, such as the ability to facilitate the release of noradrenaline from sympathetic nerve terminals in the heart, although other mechanisms may be involved.

References

Apr 1, 1975·British Journal of Anaesthesia·I R DouglasI M Ledingham
Mar 1, 1986·Journal of Cardiovascular Pharmacology·F M WilliamsJ R Parratt
Apr 1, 1983·Circulation Research·J E PérezP D Henry
Oct 15, 1982·European Journal of Pharmacology·K M MullaneS Moncada
Jul 1, 1980·Circulation Research·S WallensteinJ L Fleiss
Jan 1, 1980·British Journal of Pharmacology·R J Marshall, J R Parratt

❮ Previous
Next ❯

Citations

May 1, 1988·Cardiovascular Drugs and Therapy·J R Parratt
Jun 1, 1987·Naunyn-Schmiedeberg's Archives of Pharmacology·G Scholtysik
Jun 30, 2001·European Journal of Pharmacology·Y M LeeM H Yen
May 1, 1987·Acta Physiologica Scandinavica·L CarlssonL Svensson
May 1, 1990·European Journal of Population = Revue Européenne De Démographie·M P Gutmann, S C Watkins
Mar 1, 1990·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·M J Robinson, J McCulloch
Mar 1, 1993·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·I M MacraeJ McCulloch

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.